Identification of Residues of the IFNAR1 Chain of the Type I Human Interferon Receptor Critical for Ligand Binding and Biological Activity
Overview
Authors
Affiliations
The antiviral and antiproliferative activities of human type I interferons (IFNs) are mediated by two transmembrane receptor subunits, IFNAR1 and IFNAR2. To elucidate the role of IFNAR1 in IFN binding and the establishment of biological activity, specific residues of IFNAR1 were mutated. Residues (62)FSSLKLNVY(70) of the S5-S6 loop of the N-terminal subdomain of IFNAR1 and tryptophan-129 of the second subdomain of IFNAR1 were shown to be crucial for IFN-alpha binding and signaling and establishment of biological activity. Mutagenesis of peptide (278)LRV in the third subdomain shows that these residues are critical for IFN-alpha-induced biological activity but not for ligand binding. These data, together with the sequence homology of IFNAR1 with cytokine receptors of known structure and the recently resolved NMR structure of IFNAR2, led to the establishment of a three-dimensional model of the human IFN-alpha/IFNAR1/IFNAR2 complex. This model predicts that following binding of IFN to IFNAR1 and IFNAR2 the receptor complex assumes a "closed form", in which the N-terminal domain of IFNAR1 acts as a lid, resulting in the activation of intracellular kinases. Differences in the primary sequence of individual IFN-alpha subtypes and resulting differences in binding affinity, duration of ligand/receptor association, or both would explain differences in intracellular signal intensities and biological activity observed for individual IFN-alpha subtypes.
Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling.
Wilmes S, Beutel O, Li Z, Francois-Newton V, Richter C, Janning D J Cell Biol. 2015; 209(4):579-93.
PMID: 26008745 PMC: 4442803. DOI: 10.1083/jcb.201412049.
Oganesyan V, Peng L, Woods R, Wu H, DallAcqua W J Biol Chem. 2015; 290(24):14979-85.
PMID: 25925951 PMC: 4463443. DOI: 10.1074/jbc.M115.652156.
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody.
Peng L, Oganesyan V, Wu H, DallAcqua W, Damschroder M MAbs. 2015; 7(2):428-39.
PMID: 25606664 PMC: 4622752. DOI: 10.1080/19420862.2015.1007810.
Kinetic analysis of cytokine-mediated receptor assembly using engineered FC heterodimers.
Deshpande A, Putcha B, Kuruganti S, Walter M Protein Sci. 2013; 22(8):1100-8.
PMID: 23703950 PMC: 3832046. DOI: 10.1002/pro.2285.
Structural linkage between ligand discrimination and receptor activation by type I interferons.
Thomas C, Moraga I, Levin D, Krutzik P, Podoplelova Y, Trejo A Cell. 2011; 146(4):621-32.
PMID: 21854986 PMC: 3166218. DOI: 10.1016/j.cell.2011.06.048.